InvestorsHub Logo
Followers 154
Posts 2653
Boards Moderated 0
Alias Born 01/29/2004

Re: noretreat post# 119642

Monday, 09/11/2017 6:09:58 PM

Monday, September 11, 2017 6:09:58 PM

Post# of 464082
Anavex Announcement, Three Upcoming Trials of Anavex 2-73

http://www.anavex.com/about-us/overview/

The Company is in preparation for ANAVEX™ 2-73 for a Phase 2/3, placebo-controlled trial in [Trial One, this fall, for one year.] Alzheimer’s disease as well as a Phase 2, placebo-controlled trial in Rett syndrome, [Trial Two, for 3 months, beginning this fall.] for which the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) for ANAVEX™ 2-73 and a Phase 2, placebo-controlled trial in Parkinson’s disease. [Trial Three, starting this fall.]



Two short, 3-month trials sometime this autumn, Rett syndrom and Parkinson’s disease . A big year-long double-blind Alzheimer’s trial, starting this fall or early 2081.

Exact dates are unknown, not yet announced or perhaps not even determined.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News